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It can be difficult to accept change. When we recognize a
new trend beginning to reshape our environment, we worry
and often speculate on the worst possible outcomes. Bal-
ancing a desire for maintaining the present with the inevi-
tability of a new future is often a tough juggling act. Should
we have heralded the advent of managed care as a visionary
evolution or rejected it as a detriment to the health care of
every American? Should physicians unionize, or would
doing so deprofessionalize us and damage the sacred doc-
tor–patient relationship, rather than strengthen our position
to protect our patients? Should we fear the role that Internet
sites are beginning to play in health care, or should we work
with them to ensure that the information they offer our
patients is backed by our expertise?
And what about research? There can be no doubt that it,
too, is undergoing a transformation. . .not just what is
researched, such as molecular biology and genetics, but how
we go about it. My goal here is to explore the changing face
of research, giving equal space to some worries about the
ethical dilemmas we may confront and also to the visions of
what we may accomplish.
THE OLD MODEL
Not so long ago, academic health centers seemed to have
cornered most of the medical research market. Medical
scientists almost always worked in academia. It was the
hotbed of basic science experiments, the source of most of
the papers in the literature, and the place where industry
turned to test a new drug, device, or diagnostic advance.
From academic health centers came the data on safety and
efficacy that industry needed to obtain new product approval
by the Food and Drug Administration and to get life-saving
therapies and diagnostic procedures accepted as components
of everyday patient care.
While medical research was a collaborative effort in those
days, there was also an unmistakable line drawn in the sand
that kept marketing, sales, and profits separate from clinical
investigation. For the most part, that division was laid down
by the academic health centers, where concerns over the
bottom line, press announcements, and patent applications
were eschewed. In fact, when we implanted the first
transvenous cardioverter in two patients with monomorphic
ventricular tachycardia (1) and had both newspaper and
television coverage of the event, I was roundly chastised by
my dean for such egregious behavior. The entrepreneurial
spirit had not yet infiltrated our research culture. We were
personally to be silent about such advances and let the
published manuscript do the talking. Today, many would
say that was shortsighted, and perhaps they are right. But
research, just for the pure joy of discovery, was the motive.
And even now, at least for me, there is still no greater
intellectual thrill than creating an hypothesis, testing it at
the bench or bedside, finding it to be true, and knowing that
you have contributed a bit of information, no matter how
small, to the wealth of human knowledge, and that for a
brief moment in time, you may be the only person in the
world who possesses that tiny fact. The feeling is awesome
and motivates me to this day.
CHANGING TIMES
Gradually, over the past few years, several new paradigms
for medical research have developed. Increasingly, superb
basic science is performed in industry laboratories. By
bringing basic science “in house,” industry is capable of
competing with the academic health centers and even
entities like the National Institutes of Health (NIH). In
essence, industry has found a market for knowledge acqui-
sition. Take the Human Genome Project for example.
Companies like Celera Genomics and Human Genome
Sciences are competing with academic health centers and the
NIH to patent genetic information that may be used in their
future products. Some companies already market genetically
derived materials—unquestionably a growth area.
Just as there is certain logic in pharmaceutical and device
companies employing their own scientists and performing
their own research, there is an inherent appeal in launching
clinical trials with the participation of large private practices.
Industry no longer automatically turns to academic health
centers to conduct clinical trials on new products for several
reasons. First, there is large patient volume in these private
practices—many willing patients seeking the latest treat-
ment. Second, the doctors in these practices are actual or
potential customers of the company sponsoring the re-
search. Basing clinical trials in their examining rooms is an
ideal opportunity for industry to expose these physicians to
products they may very well prescribe in the future. Third,
many of the practices have dedicated staff, funded by the
research, that can recruit patients and gather data efficiently.
And, finally, the practice can be motivated to make money
by performing the industry-funded studies.
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THE EFFECTS
Human impulse is to judge—to declare this evolving para-
digm either good or bad and then to praise or condemn it.
So, the challenge here is to look at this new model, compare
it to the old, try to imagine what will happen next in both
best- and worst-case scenarios, and to watch carefully as it
unfolds.
There are some obvious positives, mostly the products of
collaboration and opportunity. As industry has opted to put
its dollars into its own laboratories and into private prac-
tices, the stigma scientists previously suffered when they
chose to work for industry has faded. No longer are the
motives of industry-employed researchers closely scrutinized
or labeled as greed. Now, working in industry is a viable and
acceptable option for young scientists. They present their
work at scientific meetings, serve as reviewers and publish in
premier journals, and are accepted as colleagues by the
academic scientific world. They have assured income and
research funds, without the uncertainties accompanying
research life in academia. However, the goal of research in
industry is to develop pharmaceuticals and devices that will
ultimately be products for sale. There is scant interest in
pursuing questions that have little foreseeable potential to
generate such products, and therefore the work of such
scientists must become very focused and restricted. In
academia, any interesting question can be a valid topic for
initiating research. While the latter is true, it has been said
that the problem of being a researcher in academia is that
there are no stock options!
Another change in relationships has occurred as private
practices have found ways to incorporate research into their
patient care. Opportunities for academic health centers and
private practices to collaborate have appeared. A private
practitioner might team up with a nearby university research
team, pooling their expertise. As a result, the lines separat-
ing academia from private practice have become much more
blurred.
Now, the drawbacks. One of the biggest issues surround-
ing these changes—and the one that is of most concern to
me, given my perspective as the director of cardiology at an
academic health center—is their impact on academia. The
funneling of research dollars and opportunities away from
academia has most definitely contributed to the plight of
academic health centers. Industry determines who becomes
a researcher of its products, who gets the plaudits for
publishing new information and the accoutrements accom-
panying such activities, and who gets the financial support.
Academia also suffers as we lose some of today’s best and
brightest scientists to industry, with its steady funding, its
financial rewards, and its entrepreneurial spirit. This loss
has, or will, diminish the effort given to basic research.
In addition, academic health centers are losing control
over an area in which they excel, an area where the ethical
forks in the road of potential conflicts of interest are familiar
landmarks. There are true dangers in having research
conducted by the people or in the facilities that have the
potential to personally profit from positive outcomes. An
extraordinary number of the papers we read in medical
journals and the presentations we hear at scientific meetings
are provided by experts who stand to benefit financially from
the research they are conducting. The natural rebuttal to the
potential impropriety of that fact is that these are the most
knowledgeable people on the topic. That is why industry
used them as researchers and consultants in the first place,
or why they have formed their own company, and therefore
they should be presenting the data. While this potential
conflict of interest is worrisome, it can—and must—be
surmounted. But it does require ethical astuteness from all
parties, an understanding of the need to make public one’s
affiliations and one’s financial relationship with industry.
Such information, usually considered private, is, under this
new model for research, pertinent.
It must be noted that there are potential conflicts of
interest in academia as well. In addition to their desire to
excel academically, researchers are increasingly encouraged
to work with their university technology transfer offices to
patent and commercialize their discoveries. They can face
pressures similar to their industrial counterparts.
WHAT NOW?
This paradigmatic change in the way we conduct the
research that determines how we treat our patients may
represent untold opportunities to advance medical care. Or
it may represent another blow to our already struggling
medical system. Regardless, it does present an ethical and
practical challenge that we must rise to meet. The task
before us now is to be vigilant and open-minded as these
changes continue to unfold and to speak up when we detect
a pothole in the road ahead. The academician and private
doctor working in research must collaborate and do it in a
way that avoids any conflict of interest. Because perception
often replaces reality, the best way to avert an ethical
problem is to be open about all relationships that might be
perceived as a conflict. It may be helpful to use the yardstick
of whether one would be upset if the relationship were first
divulged in a headline in the New York Times. Ultimately,
excellent research will win out, and neither academia nor
industry can afford to have failures because it is too
expensive in the long run for both. So, in the final analysis,
objectivity, accountability, and honesty must be the guide-
posts in this changing world of research.
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